United States Senator Ashley Moody has disclosed a series of stock trades, some raising questions about possible insider information use given her role in the Senate.
The standout transaction in her March 22 disclosure is the purchase of up to $250,000 in pharmaceutical giant Eli Lilly (NYSE: LLY) on March 6.
The trade raises concerns considering that Moody sits on the Senate Health Committee, which directly oversees policies affecting the pharmaceutical industry.
Picks for you
LLY stock performance
Notably, her purchase coincides with a period of volatility for LLY despite the company boasting strong fundamentals, such as its weight-loss drugs. At the time of reporting, Eli Lilly’s share price was valued at $837.57, dipping almost 5% in the past month, while LLY is up 7.6% year-to-date.
The Senate trade disclosure came just after a March 20 announcement that Eli Lilly had launched its weight-loss drug Mounjaro in India, pricing it lower than in the U.S. The move gives Lilly a head start over Novo Nordisk’s Wegovy, which is approved in India but has yet to receive a launch date.
Receive Signals on US Senators' Stock Trades
Stay up-to-date on the trading activity of US Senators. The signal triggers based on updates from the Senate disclosure reports, notifying you of their latest stock transactions.
These developments are helping the American company solidify its position as a key player in the pharmaceutical industry, alongside initiatives such as its recently announced $27 billion investment to expand U.S. manufacturing operations.
Additionally, Lily faces other growth catalysts, such as the FDA’s removal of tirzepatide from its shortage list, which forces compounding pharmacies to stop producing knockoff versions. This ensures Lilly retains exclusive market control over its weight-loss and diabetes drugs, Mounjaro and Zepbound, which posted triple-digit sales growth in Q4.
While Q4 sales of $13.53 billion narrowly missed expectations, Mounjaro surged 124%, highlighting its massive market demand.
It’s worth noting that CEO Dave Ricks recently highlighted Eli Lilly’s global growth opportunities in Mexico, Brazil, and China and its plans to launch oral GLP-1 drugs to enhance accessibility.
Beyond weight management, the company is looking into chronic disease prevention, targeting heart failure, sleep apnea, and hypertension.
Moody’s other transactions
Eli Lilly wasn’t the only stock Moody traded. She also purchased up to $250,000 in semiconductor giant Advanced Micro Devices (NASDAQ: AMD).
At the same time, she offloaded shares of Super Micro Computer (NASDAQ: SMCI), selling between $50,000 and $100,000 worth in one transaction and between $15,001 and $50,000 in another. She also executed several options trades, including full sales in diverse equities.
Moody’s total disclosed trade volume for 2025 is $1.61 million across 44 transactions.
Featured image via Shutterstock
